CX Institutional Has $391,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

CX Institutional increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 15.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,020 shares of the medical research company’s stock after purchasing an additional 397 shares during the quarter. CX Institutional’s holdings in Agilent Technologies were worth $391,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in A. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies during the 4th quarter worth about $26,000. MV Capital Management Inc. grew its holdings in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the last quarter. VisionPoint Advisory Group LLC bought a new stake in Agilent Technologies during the 4th quarter worth about $29,000. Rise Advisors LLC grew its holdings in Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after acquiring an additional 190 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new stake in Agilent Technologies during the 1st quarter worth about $34,000. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Trading Up 0.1 %

Agilent Technologies stock traded up $0.15 during midday trading on Friday, hitting $136.91. 232,512 shares of the stock were exchanged, compared to its average volume of 1,767,934. The company has a fifty day simple moving average of $132.64 and a two-hundred day simple moving average of $138.01. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35. The stock has a market capitalization of $39.94 billion, a PE ratio of 32.31, a P/E/G ratio of 4.86 and a beta of 1.05. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.03. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same quarter last year, the firm earned $1.27 EPS. Agilent Technologies’s quarterly revenue was down 8.4% compared to the same quarter last year. Equities research analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd were issued a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, July 2nd. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.22%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,916 shares of company stock worth $2,527,860. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on A shares. Jefferies Financial Group reissued a “hold” rating and set a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. Stifel Nicolaus decreased their price objective on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a report on Thursday, May 30th. Wolfe Research lowered shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Barclays decreased their price objective on shares of Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Finally, UBS Group reduced their target price on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating on the stock in a research note on Thursday, May 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $138.06.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.